Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

1.

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.

Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370.

PMID:
22147859
[PubMed - indexed for MEDLINE]
Free Article
2.

Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.

Chace MJ, Zhang F, Fullerton CA, Huskamp HA, Gilden D, Soumerai SB.

J Clin Psychiatry. 2012 Nov;73(11):1388-94. doi: 10.4088/JCP.12m07794. Epub 2012 Oct 16.

PMID:
23146199
[PubMed - indexed for MEDLINE]
3.

Confounding factors in off-label drug use.

Greenberg PE, Pike C, Sisitsky T.

Health Aff (Millwood). 2012 Feb;31(2):460; author reply 460. doi: 10.1377/hlthaff.2011.1394. No abstract available.

PMID:
22323178
[PubMed - indexed for MEDLINE]
Free Article
4.

Drug maker to pay $430 million in fines, civil damages.

[No authors listed]

FDA Consum. 2004 Jul-Aug;38(4):36-7.

PMID:
15346583
[PubMed - indexed for MEDLINE]
Free Article
5.

Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?

Gilhooley M.

Am J Law Med. 2011;37(2-3):258-77.

PMID:
21847881
[PubMed - indexed for MEDLINE]
6.

The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.

Fullerton CA, Busch AB, Frank RG.

Med Care. 2010 Apr;48(4):372-9. doi: 10.1097/MLR.0b013e3181ca404e.

PMID:
20195173
[PubMed - indexed for MEDLINE]
7.

Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.

Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K.

Trials. 2012 Aug 13;13:136. doi: 10.1186/1745-6215-13-136.

PMID:
22888801
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.

Chen DT, Wynia MK, Moloney RM, Alexander GC.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1094-100. doi: 10.1002/pds.1825.

PMID:
19697444
[PubMed - indexed for MEDLINE]
9.
10.

Off-label marketing stirs a legal hornet's nest.

Guglielmo WJ.

Med Econ. 2006 Oct 6;83(19):47-9. No abstract available.

PMID:
17066854
[PubMed - indexed for MEDLINE]
11.

Pfizer versus Kaiser: insurers want their day in court.

Silverman E.

BMJ. 2013 Jun 12;346:f3738. doi: 10.1136/bmj.f3738. No abstract available.

PMID:
23760967
[PubMed - indexed for MEDLINE]
12.
13.

Recent case developments in health law. False Claims Act: the right treatment for off-label marketing?

Wang S.

J Law Med Ethics. 2010 Fall;38(3):708-13. doi: 10.1111/j.1748-720X.2010.00524.x. No abstract available.

PMID:
20880253
[PubMed - indexed for MEDLINE]
14.

Off-label marketing: free speech or illegal promotion?

Silverman E.

BMJ. 2013 Jan 22;346:f320. doi: 10.1136/bmj.f320. No abstract available. Erratum in: BMJ. 2013;346:f793.

PMID:
23341546
[PubMed - indexed for MEDLINE]
15.

Media coverage of off-label promotion: a content analysis of US newspapers.

Joshi AD, Patel DA, Holdford DA.

Res Social Adm Pharm. 2011 Sep;7(3):257-71. doi: 10.1016/j.sapharm.2010.06.003. Epub 2010 Nov 25.

PMID:
21272550
[PubMed - indexed for MEDLINE]
16.

Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.

Melvin CL, Ranney LM, Carey TS, Evans WD, AED Dissemination Panel, Kreps G, Linden T, Oldham J.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:44-56. doi: 10.1097/01.pra.0000333587.68118.9e. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034209
[PubMed - indexed for MEDLINE]
17.

Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2011 Jun;23(4):7. No abstract available.

PMID:
21702115
[PubMed - indexed for MEDLINE]
18.

Off-label marketing and the First Amendment.

Boumil MM.

N Engl J Med. 2013 Jan 10;368(2):103-5. doi: 10.1056/NEJMp1214926. Epub 2012 Dec 12. No abstract available.

PMID:
23234470
[PubMed - indexed for MEDLINE]
Free Article
19.

Off-label prescribing among office-based physicians.

Radley DC, Finkelstein SN, Stafford RS.

Arch Intern Med. 2006 May 8;166(9):1021-6.

PMID:
16682577
[PubMed - indexed for MEDLINE]
20.

Patterns of prescribing antiepileptic drugs for bipolar disorder.

Kish-Doto J, Evans WD, Squire C, Williams P, Ranney LM, Melvin CL.

J Psychiatr Pract. 2008 Mar;14 Suppl 1:35-43. doi: 10.1097/01.pra.0000333586.60494.9a. Erratum in: J Psychiatr Pract. 2008 May;14(3):193.

PMID:
19034208
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk